Why the study?
Does the addition of bevacizumab to anticancer therapy increase the risk of high-grade adverse events in patients with advanced or metastatic breast cancer?
Population
6,260 patients with advanced-stage breast cancer from 12 RCTs
Comparison
Bevacizumab added to anticancer therapy vs Alternative treatment
Design
Meta-analysis
Authors
Loading...
Requires vigilant monitoring for high-grade toxicities with bevacizumab in metastatic breast cancer; confirms and extends hypertension risks to other adverse events.
Does the addition of bevacizumab to anticancer therapy increase the risk of high-grade adverse events in patients with advanced or metastatic breast cancer?
The addition of bevacizumab to anticancer therapy in advanced breast cancer significantly increases the risk of severe adverse events, including hypertension and cardiac toxicity.
Shin et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: